Medsider: Learn from Medtech and Healthtech Founders and CEOs (Scott Nelson)

In this episode of Medsider Radio, we sat down with Dan Zavorotny, co-founder of Nutrisense

Before co-founding Nutrisense, Dan worked as a healthcare management consultant at KPMG, where he advised Fortune 500 companies and three of the top five hospitals in the US. His company, Nutrisense, combines continuous glucose monitoring with personalized dietitian coaching to help people optimize their metabolic health based on real-time data. 

In this interview, Dan shares the pros and cons of running a DTC healthtech business, creative recruitment strategies, and the importance of early-stage customer feedback. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Dan if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Sean Morris, CEO of Amplifi, developers of the groundbreaking Vein Dilation System to improve access sites for dialysis patients.

Sean started his professional journey selling medical devices for AngioDynamics. Over his ten-year tenure with the company, Sean rose through the ranks to become the Global Vice President of Marketing and later led the entire Peripheral Vascular Division. After leaving AngioD in 2009, he embarked on various entrepreneurial ventures, including the founding of Veniti, which was acquired by Boston Scientific in 2018. He also spearheaded Euphrates Vascular, an innovative startup in the field of microvascular obstructions.

In this interview,  Sean shares the story — from his first job selling medical devices for AngioDynamics to his current role as CEO of Amplifi, how his novel Vein Dilation System is poised to revolutionize dialysis patient care, and the many lessons he’s learned bringing innovative medtech products to market as a startup CEO.

Before we dive into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd much rather read, here's a link to the full interview with Sean Morris.

In this episode of Medsider Radio, we sat down with Waqaas Al-Siddiq, CEO of Biotrocity, a cutting-edge remote patient monitoring company focusing on the cardiac landscape. 

Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration and a Doctorate in Business Administration from Henley Business School. With over 15 years of experience in the technology and healthcare sectors, Waqaas has a strong track record of developing innovative solutions for remote patient monitoring and connected health. As the CEO of Biotricity, he leads the company's mission to revolutionize remote patient monitoring by leveraging cutting-edge technology and data-driven insights.

In this interview, Waqaas discusses the crucial role that passion and work ethic play in driving healthtech success. He shares valuable insights into understanding the needs of your target market for effective product development, as well as fostering a culture of continuous learning and improvement within your organization.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Shriram Raghunathan, a neuroengineering pioneer and CEO of Noctrix Health.

Shri has been leading his team in the development of innovative solutions to improve the lives of patients with neurological disorders like restless leg syndrome, aiming to level the playing field between medical devices and pharmaceuticals in patient care.

In this interview, Shri talks about how a mindset of exploration has driven his venture into the development of novel medical solutions within the challenging terrain of neurology. He also offers valuable insights on the critical importance of focusing on unmet needs, building a high-performance team, and navigating regulatory and capital-raising challenges. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Shriram if you prefer reading.

In this episode of Medsider Radio, we had an insightful discussion with Timothy Boire and Geoffrey Lucks, co-founders of VenoStent. The company is developing SelfWrap, a bioabsorbable wrap to improve the success rate of vascular surgeries, starting with dialysis access creation for chronic kidney disease (CKD) patients.   

Tim holds a Ph.D. in Biomedical Engineering from Vanderbilt University. He has experience as a Research Associate at Genzyme and was an Entrepreneurial Lead at NSF I-Corps. Geoffrey is a venture partner at Pioneer Fund and has a BA in Economics, Biology, and Zoology from the University of Wisconsin, a Master's in Bioethics from the University of Pennsylvania, and an MBA in Finance from Vanderbilt University.
 
In this interview, they talk about understanding your end user, working collaboratively with FDA, structuring and executing large clinical trials, and staying resourceful to attract funding while developing your concept.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Tim Boire and Geoffrey Lucks.

In this episode of Medsider Radio, we had a compelling chat with Beth Rogozinski, CEO of Oncoustics. The company uses advanced AI to analyze ultrasound data to offer a cost-effective alternative to traditional diagnostic methods. 

Beth has held a variety of leadership roles in the field of digital health, including the development of the first FDA-cleared prescription digital therapeutic. She advises numerous startups and accelerators and has consulted with organizations like Stanford, UnitedHealth, and the National Mental Health Innovation Center. She is a guest lecturer at UCSF Health Hub and Columbia’s HIT Lab and serves on BIO’s Digital Health committee. 

In this interview, Beth shares her insights on the importance of persistence and resilience in fundraising, the value of engaging with a diverse range of investors, and the need for a strong narrative about your technology, particularly when it involves AI capabilities.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Beth Rogozinski.

In this episode of Medsider Radio, we sat down with, Tim Rosa, CEO of Somnee, a company developing wearables based on personalized neuroscience to improve sleep quality. 

Previously, Tim was the CMO at Fitbit, where he played a key role in establishing the health and fitness wearables category. He built the organization’s global marketing function, contributing to the sale of over 140 million devices in 100+ countries. Additionally, he helped drive the company’s IPO and its eventual $2.1 billion sale to Google. Tim has also advised and worked with major brands like Electronic Arts, 2K Sports, ESPN Video Games, and Jasper Health.

In this interview, Tim shares insights on building and scaling successful brands based on real customer experiences, keeping messaging clear, and using brand strategy as a business foundation. He also shares why solid data and clinical evidence in OTC products are essential and how he generates value out of ongoing research.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Tim Rosa.

In this episode of Medsider Radio, we sat down with Marc Zemel, CEO of Retia Medial.

Marc has extensive experience in fundraising for successful startups and is an experienced leader of Fortune 500 companies. Prior to founding Retia Medical, Marc earned an MS in Mechanical Engineering from MIT and an MBA in Sales and Marketing from Yale. He’s also held key leadership roles at Becton Dickinson as well as a capital equipment start-up.

In this interview, Marc talks about managing a medtech start-up that’s developing groundbreaking technology while pursuing fundraising that drives sustainable growth.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Marc if you'd rather read it instead.

In this episode of Medsider Radio, we had a riveting chat with David Hochman, founder and CEO of Orchestra BioMed, a company accelerating high-impact technologies through risk-reward-sharing partnerships with leading medical device companies.

David has over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking. He has a history of leading successful medical startups, including Orchestra Medical Ventures and Accelerated Technologies. As Chairman of Motus GI and former board member of Corbus Pharmaceuticals and PROLOR Biotech, David has been instrumental in advancing medical technologies, contributing to significant mergers & acquisitions, and many fundraising successes.

In this interview he talks about driving successful partnerships, operational excellence in R&D, and the importance of a long-term strategy for sustainable industry innovation through aligned incentives.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with David Hochman.

In this episode of Medsider Radio, we sat down with Brett Wingeier, co-founder and CTO of Magnus Medical, a privately held medical device company whose FDA-cleared SAINT™ Neuromodulation System aims to revolutionize mental health care. 

Brett is a prominent figure in neuromodulation, leveraging his expertise in medicine, biology, and engineering to advance the arena within medtech. He was part of the pioneering team at NeuroPace and also co-founded Halo Neuroscience. 

In this interview, Brett shares valuable insights into understanding the system you're working with, balancing consumer and provider perspectives, and ensuring cost-effectiveness for successful reimbursement.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Joe Landolina, co-founder and CEO of Cresilon, developers of a groundbreaking technology that's pushing the boundaries of what's possible in the field of trauma care.

Joe was introduced to chemical lab research at a young age, which kindled a lifelong interest in discovering responsive, nature-derived materials. Embarking on his journey as an entrepreneur and innovator at only 17, Joe invented the technology behind Vetigel, a major breakthrough in the trauma field.

In this interview, Joe reveals the development process behind Vetigel, an innovative product that stops severe bleeding with remarkable speed. Joe expounds on the unorthodox paths he took to build the company and the importance of a well-rounded team that’s able to balance creative and conservative strategies.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Konrad Morzkowski, co-founder and CEO of WearLinq. The startup is commercializing eWave, an FDA-cleared EKG monitor for continuous cardiac monitoring. 

Konrad is an engineer from Sweden and a member of Forbes’ 30 under 30 list. After obtaining an MS at Stanford – where he met his co-founders and raised his first round – Konrad dove right into entrepreneurship with WearLinq, a company commercializing consumer-facing digital healthcare solutions with an initial focus on EKG monitoring. 

In this interview, Konrad shares how he optimizes fundraising efforts by aligning them with important milestones, his unconventional methods to gather voice of customer research, and how his startup moved rapidly through product design iterations. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Konrad Morzkowski.

In this episode of Medsider Radio, we sat down with Deanne McCarthy, founder and CEO of Swiftsure Innovations, a company developing a device capable of safely and effectively cleaning the oral cavity of patients on life support. 

Deanne was a critical care nurse before she decided to make the switch to medtech entrepreneur. With Deanne's commitment to empowering nurses and enhancing patient outcomes, Swiftsure has assembled an adept team and a robust group of advisors that has enabled the company to move incredibly quickly across key functions like product development, regulatory affairs, and commercialization. 

In this interview, we explore the invaluable role of mentors and connections in Deanne's journey, her insights on accelerator programs, and how her initial lack of startup experience gave her the tenacity to seek out and validate collaborative partners. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Deanne McCarthy.

In this episode of Medsider Radio, we sat down with Torrey Smith, co-founder and CEO of Endiatx.

Torrey founded Endiatx alongside fellow Silicon Valley technology experts Dan Moyer, James Erd, and Alex Luebke. After leaving a different medical device company to scratch his entrepreneurial itch, Torrey and his co-founders are developing a new technology that aims to lower the barrier for patients to get diagnosed and treated for gastrointestinal diseases. 

In this interview, Torrey discusses the importance of both in-person and online networking, and best practices for sharing your product development progress with the investment community, stakeholders, and target patients. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Torrey if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Dr. Ohad Arazi, CEO of Clarius, a leading provider of high-definition wireless ultrasound systems. 

With his extensive experience in the technology industry, ranging from the Israeli military to industry leaders like McKesson, Telus, and Zebra Medical, Ohad's impact on Clarius' persistent growth is undeniable.

In this interview, Ohad shares the inspiring story of Clarius and its innovative handheld ultrasound device. From navigating regulatory hurdles to training audiences on new technology, Ohad explains how Clarius has achieved impressive growth year after year and shares valuable insights relevant to any medtech startup.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Ohad if you'd rather read the summary instead.

In this episode of Medsider Radio, we had an enlightening conversation with Ken Mariash, a leading figure in the neuromodulation space and the CEO of Sinaptica Therapeutics, where his team is developing groundbreaking treatments for Alzheimer's disease. Their device delivers non-invasive neuromodulation therapy to key networks of the brain and has shown unprecedented improvement in treating this debilitating disease. 

Ken's two decades of experience leading sophisticated organizations has taken him from management consulting at Charles River Associates to significant roles at CSL, Baxter, and Boston Scientific. During his time at Boston, Ken was instrumental in commercialization and strategy development in the company’s $1B neuromodulation division. 

In this interview, Ken shares his time-tested wisdom, covering a range of topics from kick-starting a venture and how to approach M&A transactions, to mastering commercialization and best practices for engaging with investors.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Ken Mariash.

In this episode of Medsider Radio, we sat down with medtech veteran Joe DeVivo, President and CEO of Butterfly Network. Butterfly iQ3 is the startup's latest chip-powered, hand-held ultrasound device with superior image quality and ultrafast scan times. 
 
Joe is a proven executive with 35 years of business leadership experience, including 22 years in the medical device industry spanning small start-up companies to multi-billion-dollar organizations. He has acquired and fully integrated eight companies, engineered four business turnarounds, and delivered five company exits. 

In this interview, Joe shares insights on why a lean start in commercialization is better than a high-burn, high-risk approach, the difference between your company being sold and being purchased, and best practices for managing M&A transactions. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Joe DeVivo.

In this episode of Medsider Radio, we sat down with Will Martin, CEO of IRRAS, a company revolutionizing the treatment of intracranial bleeding.

Will is an accomplished executive with over two decades of hands-on experience in the medtech arena, including roles at Boston Scientific, Access Closure, Hotspur Technologies, and Athromed. Will's expertise in sales and marketing leadership propelled him to become the CEO of IRRAS. His contributions to startups and established strategics have solidified his reputation as a proven leader in the medical device space.

In this interview, Will shares his insights on understanding user needs and cultivating strong internal relationships while maintaining robust quality management systems.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we had a fun chat with Trent Reutiman, CEO of Mercator MedSystems. Trent and his team have developed microinfusion devices with the unique ability to locally and directly deliver targeted therapeutics during catheter-based interventions where mechanical therapy isn’t sufficient.
 
Trent has 25 years of leadership experience in medtech including roles in sales, marketing, and business management with a focus on minimally invasive interventional products for companies like IDEV, ROX Medical, RITA Medical Systems, Guidant, and Cordis.

In this interview, Trent talks about the importance of generating data, how to balance commercial efforts with clinical initiatives, and why meticulous management is critical for successful commercialization. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Trent Reutiman.

In this episode of Medsider Radio, we sat down with Kirsten Carroll, CEO of Kandu Health, and a medtech veteran specializing in neurovascular disorders with nearly 25 years of experience in the field. 

Kirsten holds a degree in biomedical engineering and dual master's degrees in business and public health. She has held strategic roles at industry leaders like Boston Scientific and Stryker before joining Imperative Care and co-founding Kandu Health. Her startup focuses on revolutionizing post-stroke care and enhancing the quality of life for stroke survivors through tech-enabled healthcare services.

In this interview, Kirsten talks about redefining post-stroke care with a comprehensive set of services to improve the well-being of stroke survivors and, consequently, their care partners. From her unique perspective on innovation to her emphasis on a multi-stakeholder approach, Kirsten shares invaluable lessons on breaking down monumental challenges and fostering a culture of teamwork.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Kirsten Carroll.

In this episode of Medsider Radio, we sat down with Cecile Brosset Dubois, CEO of Sonio, a company dedicated to revolutionizing obstetric ultrasound through AI technology. 

Cecile began her career in 2005 at Capgemini, later advancing to Bain & Company. Her strategic insights as Head of Strategy at FSI - Fonds Stratégique d'Investissement - and her pivotal roles at Bpifrance set the stage for Cecile's entrepreneurial journey. At Kamet Ventures, she fully embraced the startup world before eventually co-founding Sonio. 

In this interview, we touch on her strategic approach to product development, the importance of an in-house regulatory team, her drive for meaningful work, and effective tactics for fundraising.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Cecile Brosset.

In this episode of Medsider Radio, we sat down with Jason Hannon, President and CEO of Mainstay Medical, where he and his team are commercializing ReActiv8, an implantable neurostimulation system for intractable mechanical chronic low back pain. 

Jason holds a J.D. from Stanford University Law School and a B.A. from the University of California, Berkeley. After 12 years at NuVasive, where as COO, he led the company to incredible revenue milestones, he transitioned to his current role at Mainstay.
 
In this interview, Jason shares his experiences on iterative product development, considerations for clinical trial design, the importance of patient education, and why reimbursement is paramount.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Jason Hannon.

In this episode of Medsider Radio, we sat down with Bill Colone, the CEO and Chairman of SinglePass, a company developing an electrocautery device for deep tissue biopsies.

Bill previously headed Spinal Singularity, raising over $11 million for product and clinical development. He was VP of R&D at Direct Flow Medical and the President of Endomed, which was sold in 2005. Bill also served in multiple leadership roles at Endologix and holds 13 U.S. patents with more pending. He earned his bachelor's in Chemical Engineering from Arizona State University, where he later served as an Associate Faculty Member and sits on the advisory committee for Chemical and Materials Engineering.

In this interview, Bill shares invaluable insights and actionable strategies for building and leveraging an expansive network, optimizing fundraising, and strategically planning for both acquisition and independent growth.
 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Bill Colone.

In this episode of Medsider Radio, we had a fun conversation with Kevin Eisenfrats, CEO of Contraline. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.

Kevin is a first-time entrepreneur and nanomedical engineer from the University of Virginia (UVA) and has been working on contraceptive technologies since his undergrad years. He has amassed over 50 patents in contraceptive drugs, medical devices, and biomaterials. In 2017, he was honored with a place among the Forbes 30 Under 30 in Healthcare.

In this interview, Kevin offers insights on how to move swiftly through clinical trials, community-building in medtech, creative fundraising efforts, and the importance of executing thorough scientific and market research.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Kevin Eisenfrats.

In this episode of Medsider Radio, we sat down with Harlee Sorkin, CEO of InterShunt Technologies, a startup developing a minimally invasive catheter designed to treat heart failure. By improving blood flow and lessening the heart's workload via a shunt, the company's technology holds promise for easing heart failure symptoms.

Harlee is a co-founder of Common Place Holdings, a venture studio that has spun out eight medtech startups, including InterShunt. Before Common Place, Harlee led Traco Labs, a health and nutrition ingredient manufacturer, to a successful exit. He also served as the Clinical Assistant Professor at the University of Illinois at Urbana-Champaign, where he focused on translating research ideas into commercially viable applications. 

In this interview, Harlee delves into the nuances of leading an early-stage medtech company and covers essential topics such as development prioritization and capital fundraising. He also shares what it’s like to navigate clinical and regulatory challenges as a first-time medtech entrepreneur and how to effectively engage with stakeholders across the healthcare ecosystem.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Harlee Sorkin.

In this episode of Medsider Radio, we had an insightful chat with Amarpreet Sawhney, inventor, serial entrepreneur, and CEO of a few startups, including Instylla, which is developing polymerizing liquid embolics that can be used to shut down blood supply to hypervascular tumors and control bleeding.

Amar is also the CEO of Rejoni, Sealonix, and Pramand. His FDA-approved inventions include ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Together, they have impacted over 8 million patients globally.

In this episode, Amar shares his frameworks on risk assessment for medtech startups, tips on clinical study design, and how to prioritize indications when working on platform technologies.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Amar Sawhney.

In this episode of Medsider Radio, we sat down with Dr. Sam Mazin, CEO of RefleXion, a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy.

 
Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. 

In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Sam if you'd rather read the summary instead.

In this episode of Medsider Radio, we had an engaging conversation with Marissa Fayer, CEO of DeepLook Medical. This startup is developing AI-powered diagnostic tools that help radiologists detect cancerous lesions in dense tissue.
 
Marissa has over two decades of experience as a medtech executive, entrepreneur, investor, and philanthropist, spanning companies like Hologic and Olympus. She’s the founder of HERhealthEQ, a non-profit focused on advancing global women's health, and an entrepreneur-in-residence at Graybella Capital and Goddess Gaia Ventures. She’s a TEDx Speaker, a UCSC Miller Center Social Entrepreneur Fellow, and winner of the 2022 First in FemTech award.
 
In this interview, Marissa talks about the basics of product development, how to build iteratively, tips on identifying ideal regulatory pathways, and how she picks her advisors and board members.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Marissa Fayer.

In this episode of Medsider Radio, we sat down with Angus McLachlan, CEO of Liberate Medical, a company pioneering a non-invasive neuromuscular electrical stimulator to prevent muscle weakening in patients who rely on a ventilator to breathe.

Angus has a rich academic and professional history that intersects engineering and healthcare. Originating from Scotland, Angus began his academic journey in mechanical engineering at the University of Glasgow. This laid the foundation for his PhD research focused on electrical muscle stimulation for spinal cord injuries. His innovative work gained the attention of Apellis Pharma, leading to a collaboration that propelled the launch of his own company, Liberate Medical. 

In this interview, we talk about Angus’s do-it-yourself philosophy, how a deep understanding of the technology you’re developing gives you leverage across multiple functions, and the nuances of pitching to investors.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Angus McLachlan.

In this episode of Medsider Radio, we sat down with David Narrow, CEO of Sonavex, who has previously worked with multinational medical device companies on their commercialization and long-term business strategies as a healthcare consultant for Health Advances. 

David earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016 and 40 Under 40 by the Baltimore Business Journal in 2017.

In this interview with David, we talk about the art of perfecting product design, the strategies to adeptly navigate complex regulatory waters, and the nuances of capturing the trust and interest of venture capitalists. 

Before we dive into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with David if you prefer reading.

In this episode of Medsider Radio, we sat down with Mark Carbone, CEO of PN Medical.

Mark is the CEO of PN Medical, makers of medical devices that help improve pulmonary performance of patients, vocal artists, and professional athletes. Mark used his technology background and entrepreneurial experience to turn PN Medical into a frontrunner in the pulmonary space.

In this interview, Mark shares crucial lessons on how business leaders should build teams, bring a device to market, and protect the company’s brand.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Mark if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Mara McFadden CEO of Endolumik, developers of an innovative fluorescence-guided esophagogastric calibration system. 

Mara graduated as a mechanical engineer from the University of California, Berkeley. She further developed her business acumen during her MBA at Carnegie Mellon University and in various leadership positions with renowned healthcare companies such as Johnson & Johnson and Philips Healthcare. 

Mara co-founded Endolumik, and in this interview, shares her philosophy of embracing imperfections and learning from your failures, why customer engagement and team culture are integral to business growth, and how the art of smart fundraising can lead to a thriving venture.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Gabriel Jones, co-founder and CEO of Proprio, who has had a career spanning engineering, law, finance, and philanthropy across the world. 

Gabriel studied engineering at the University of Washington before furthering his career at Tase Kensetsu, a major civil engineering and manufacturing firm in Japan. He then moved to Wall Street to work on large-scale mergers and acquisitions for high-profile clients like AT&T and Google. After returning to Seattle, Gabriel collaborated with the Bill & Melinda Gates Foundation on global healthcare initiatives. Today, he is the CEO of Proprio, a revolutionary medtech startup aiming to improve surgical precision with AI-powered technology.

In this interview, the eclectic Gabriel shares how his background has equipped him with a unique framework for creating a thriving startup ecosystem, tips on capital fundraising, and using public relations to his favor.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor! 

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Gabriel Jones.

In this episode of Medsider Radio, we sat down with Tim Blair, CEO of ICHOR, an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.

With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Kate Rumrill, CEO of Ablative Solutions, a clinical-stage medical device startup specializing in transcatheter perivascular alcohol denervation for hypertension.

Kate is an accomplished leader with over three decades of comprehensive experience within the medtech and pharmaceutical industries. She brings a unique blend of expertise to the table, spanning roles from clinical affairs to executive management, with pivotal stints at prominent companies such as Eli Lilly and Covidien.

Her journey from being an aspiring neurosurgeon to leading a life sciences startup underscores the power of seizing unexpected opportunities. In this interview, Kate dives into her three-decade-long career and provides valuable lessons on the importance of thorough research, strategic clinical trial design, and effective reimbursement strategies.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Kate if you prefer reading.

In this episode of Medsider Radio, we had a fascinating discussion with Daniel Powel, CEO of Spark Biomedical, the company behind Sparrow Ascent, a drug-free wearable device to combat opioid withdrawal symptoms. It is also advancing neurostimulation technology to address Neonatal Opioid Withdrawal Syndrome. 

Daniel found his true passion in medical devices, specifically neurostimulation, in 2006 and has since launched multiple products in the space for companies like St. Jude Medical, LivaNova, and Getinge. He co-founded Spark Biomedical in 2018, which now has two FDA-cleared devices to treat opioid addiction.

In this interview, Daniel shares key insights from his journey: the importance of testing ideas and creating a MVP, diversifying funding sources, and how to make informed regulatory decisions.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Daniel Powell.

In this episode of Medsider Radio, we sat down with Parag Gad, who founded SpineX to turn cutting-edge science into life-changing devices. The FDA has granted Breakthrough Device Designation for two of SpineX's non-invasive products aimed at improving the lives of adults with neurogenic bladder conditions and children with cerebral palsy.

Parag understands both sides of the coin — the research-intensive academic world and the rigorous standards of healthcare regulation. With SpineX, he's marrying the two, aiming for a transformation in spinal healthcare. The company has raised $3.6 million in equity financing and has also secured non-dilutive funding from government agencies. With ongoing multicenter clinical trials and plans for future enrollment, Parag is steering SpineX toward a new frontier in bioelectric medicine.

In this interview, Parag delves into the intricate journey of transitioning from academia to entrepreneurship, securing non-traditional funding, and the role of regulatory milestones in building a reputable healthcare brand.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Parag Gad.

In this episode of Medsider Radio, we sat down with Tess Cosad, a femtech enthusiast and CEO of Béa Fertility. Béa offers effective, hormone-free, affordable, at-home fertility treatments and ovulation tracking as an alternative to traditional clinic-based offerings. 

Before Béa, Tess founded Emberson Ventures, a B2B marketing agency, and Hers By Design, a femtech company. She was also the first woman to lead a digital marketing-focused accelerator program in Saudi Arabia.

In this interview, Tess delves into the challenges and triumphs of launching a consumer-facing product, the importance of a solid design team, how to be comfortable making decisions with imperfect information, and the lessons she learned about being a CEO while raising funds.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Tess Cosad.

In this episode of Medsider Radio, we had a fun discussion with Nick Delmonico, CEO of Strados Labs, the company developing a wearable stethoscope to remotely capture lung sounds.  

Nick boasts a dynamic background with an MBA from the Fox School of Business at Temple University and a Bachelor's in Accounting from the University of Delaware. His career includes roles at ECG Management Consultants, PwC, and J.P. Morgan, where he honed his skills in healthcare strategy, commercialization and operations, business planning, and project management.

In this interview, Nick talks about how Strados validated its technology through others' research and how starting with a clear understanding of the problem, rather than jumping straight to offering solutions, created significant opportunities for his company. He also emphasizes why interpersonal skills and active listening are crucial to success in medtech, and shares strategies for non-dilutive funding as a way to alleviate initial capital constraints while building credibility at the same time.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Nick Delmonico.

In this episode of Medsider Radio, we sat down with Dave Kuraguntla, co-founder and CEO of Alio, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. 

Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with John Bertrand, the CEO of Digital Diagnostics, a company that is pioneering AI healthcare systems. Its flagship product, LumineticsCore, is an algorithm that autonomously diagnoses patients with diabetic retinopathy. 

John's career started at Epic Systems, where he rapidly advanced through various roles, focusing on product and business development. His expertise in digital healthcare, honed at Epic, led to his role at 8VC, a Silicon Valley venture capital firm, where he concentrated on artificial intelligence in medical imaging. Eventually joining Digital Diagnostics as CEO, John combined his extensive industry experience with a passion for innovative healthcare technology solutions.

In this interview, John shares his insights on aligning products with real-world needs, the importance of stakeholder engagement for adoption and long-term success, and strategies for navigating the extended sales cycles in healthcare technology. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with John Bertrand.

In this episode of Medsider Radio, we sat down with Derek Herrera, founder and CEO of Bright Uro.

Derek served as an elite Marine officer in the U.S. military before suffering debilitating injuries while in the line of duty. Using his personal experience, he founded UroDev Medical, Habit Camera, and Bright Uro. His latest venture aims to launch an innovative urology device that’s meant to replace an invasive bladder diagnostic test that hasn’t changed in decades. 

In this interview, Derek shares important lessons in driving device innovation, running a medtech startup, and developing products efficiently.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Derek if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with medtech veteran, Eric Goslau, the co-founder and CEO of Transverse Medical. His startup is developing the Point Guard Cerebral Embolic Protection device that shields the brain from debris during cardiovascular procedures, reducing the risk of strokes.
 
Co-inventor of Point Guard, Eric has 29 years of experience in leadership roles across sales, marketing, and product development. At Transverse, Eric oversees all aspects of the company, including fundraising, clinical planning, and regulatory strategy. He has successfully raised over $14 million through innovative financing strategies.

In this interview, Eric shares how his background in sales helps him manage various functions of the company, how fundraising cycles have worked for Transverse, and his philosophy when it comes to product development: the enemy of good is perfect.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Eric Goslau.

In this episode of Medsider Radio, we had an engaging conversation with Bill Snyder, CEO of Vivante Health, a startup commercializing an all-in-one digital platform for digestive health conditions. GIThrive is a platform that combines data-driven technology with a team of physicians, registered dietitians, and health coaches to deliver personalized care.

With over 15 years of experience in healthcare technology, Bill's background includes building and leading national sales efforts at Virta Health and overseeing their health plan practice. Previously, he spent 11 years at Humana in various leadership roles, including Vice President of the company's greater Chicago region.

In this interview, Bill talks about the importance of finding where your company stands in the overall healthcare ecosystem, why clinical outcomes and sorting out reimbursement are critical to survival, and his experiences raising capital for Vivante.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Bill Snyder.

In this episode of Medsider Radio, we sat down with Kelly Roman, co-founder and CEO of Fisher Wallace, a company spearheading the development of wearable brain stimulation technology aimed at providing relief from depression, anxiety, and insomnia. 

Kelly is a Harvard graduate with an English major who took an unconventional path to medtech inspired by his experience co-authoring the graphic novel adaptation of Sun Tzu's "The Art of War." He took a career leap from literature and marketing to pioneer a novel approach to the treatment of mental health. 

In this interview, we delve into what Kelly's learned on his journey, touching on the value of unconventional thinking, the importance of making mental health treatments more accessible and less stigmatized, and the potential of decentralized clinical trials.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Kelly Roman.

In this episode of Medsider Radio, we sat down with Lloyd Mencinger, CEO of Aqua Medical, developers of a platform technology for vapor-based endoscopic ablation designed to treat type 2 diabetes with a 30-minute outpatient procedure. 

 
Lloyd is a high-energy CEO with decades of international experience in medical device sales, marketing, and business development. He has a strong track record of delivering results in both blue-chip and early-stage companies, including Boston Scientific, Edwards Lifesciences, and Baxter Healthcare. 

In this interview, Lloyd highlights the critical role of capital efficiency and rapid iteration in the early-stage development of medtech startups. He also discusses the importance of driving value for the company versus solely focusing on an acquisition. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Lloyd if you'd rather read the summary instead.

In this episode of Medsider Radio, we had a fascinating chat with Dmitri Leonov, co-founder and CEO of Taopatch USA. The company is commercializing a range of wearable nanotechnology light therapy devices aimed at managing neurological conditions including pain management and sports performance. 
 
Dmitri is also an advisor in a number of transformative technology projects. After seven fruitful years at Overture and later at Yahoo, he dove into the startup world. He went on to found several companies, including Sanebox.com, but was intrigued by frequency medicine and started his current venture by bringing Taopatch to the United States from Italy, where it was first invented.

In this interview, Dmitri shares how the company was able to garner unique publicity and how strategic partnerships with holistic practitioners, authentic user testimonials, and a creative money-back guarantee strategy were instrumental in Taopatch USA's market success.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Dmitri Leonov.

In this episode of Medsider Radio, we had an enlightening discussion with Dan Rose, former CEO of LimFlow, which recently sold to Inari Medical. The minimally-invasive LimFlow System is designed to bypass blocked arteries in the leg and rush blood back into the foot, potentially avoiding major amputation, resolving pain, and promoting wound healing.

A leader with 25 years of experience in the medical device space, Dan has worked in both multinational corporations and startup ventures throughout his career. He holds a BA and an MA from the University of Virginia, and an MBA from the Darden Business School. Most recently, he led LimFlow’s exit to Inari as the company’s CEO and has held pivotal positions at Direct Flow Medical, Sequana Medical, Medtronic, and other medtech companies. 

In this interview, Dan shares his extensive wisdom on M&A transactions, engaging with investors while maintaining business autonomy, the importance of developing with the ‘average user’ in mind, and the significance of early dialogue with regulatory bodies.

 
Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Dan Rose.

In this episode of Medsider Radio, we had a chat with Dr. Alberto Rodriguez-Navarro, CEO of Levita Magnetics, a startup aiming to make surgical procedures as minimally invasive as possible with its advanced magnetic technology. 

Dr. Rodriguez-Navarro is not only a skilled surgeon but a medtech visionary with multiple patents to his name. Discover Alberto's journey spanning his childhood fascination with using magnets to clean the inside of his turtle tank to leveraging this concept into a cutting-edge magnetic surgery platform.  

In this interview,  Dr. Rodriguez-Navarro discusses what to consider when starting a new business, how to hone your framework when transitioning from the clinic, and early-stage strategies to ease the road to FDA approval.
 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Dr. Rodriguez-Navarro.

In this episode of Medsider Radio, we had a fun and insightful conversation with Benjamin Sexson, co-founder and CEO of Monogram Orthopedics. At Monogram, Ben and his team are developing a fully autonomous robotic system for knee replacement surgery.
 
Benjamin's tenure at Pro-Dex, one of the world's top manufacturers of orthopedic robotic components, eventually brought him to lead the development and launch of Monogram’s flagship product mBôs. Ben has authored multiple patents and previously founded Brides & Hairpins, a successful B2B retail brand. He holds a bachelor’s degree in mechanical engineering with honors from Caltech and is a CFA charterholder.

In this interview, Ben talks about the importance of a good team and a liberating company culture as well as the importance of believing in what you’re doing and openly reassessing its validity regularly. He also elaborates on Monogram’s daring strategies for validating its technology and walks us through the pros and cons of crowdfunding and going public.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Benjamin Sexson.

In this episode of Medsider Radio, we had an engaging chat with Reinhard Krickl, CEO of Phagenesis, a startup commercializing a neurostimulation system designed to treat dysphagia, a condition that impairs a patient's ability to swallow.

An Austrian engineer with over 25 years of experience in medtech, Reinhard specializes in neurology-based medical devices. After beginning his career in academia, he got his industry start with Medtronic in 2000, where he would eventually lead the company’s efforts with deep brain stimulation (DBS) therapy across Europe. He is also an INSEAD-certified director and serves on several boards, chairing two of them.

In this interview, Reinhard shares insights on the importance of simplicity in design, what thorough market understanding truly means, and how he engages with stakeholders effectively. He also reveals the “market access checklist” he uses before entering the commercialization stage.
Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Reinhard Krickl.

In this episode of Medsider Radio, we had an insightful discussion with Dr. Eric Fain, CEO and President of Procyrion — a startup developing an advanced percutaneous mechanical circulatory support device for patients with chronic heart failure.  

Eric began his career at Ventritex, a startup focused on implantable defibrillators. Over the next 30 years, and through the company’s acquisition by St. Jude Medical, he has held a number of leadership roles overseeing global sales, marketing, R&D, and clinical, eventually becoming the Group President via St. Jude’s exit to Abbott. 

In this interview, Eric shares his expertise in managing startup finances, attracting investors through strategic planning, drawing up clear clinical roadmaps, and engaging with payers to catalyze commercialization. 

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Dr. Eric Fain.

In this episode of Medsider Radio, we had a chat with Tyler Melton, the co-founder and CEO of Corveus Medical, a Houston-based startup on a mission to redefine heart failure treatment. 

Tyler previously worked at Accenture, consulting for top-tier pharmaceutical companies, and at the J&J Center for Device Innovation, where he honed his skills in strategic planning and financial modeling. He then joined the Texas Medical Center Biodesign Program, where he uncovered his current mission: to treat heart failure with targeted nerve ablation. 

In this interview, Tyler shares how using off-the-shelf products for early prototypes saved him both time and money and how accelerator programs provided the networking boost his startup needed to tackle the demanding PMA regulatory pathway.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Tyler Melton.

In this episode of Medsider Radio, we’re sitting down with Kevin Goodwin, the CEO and founder of EchoNous. 

Kevin has already been part of a medical first. In 1998, he founded Sonosite, which released the first point-of-care ultrasound device (PoCUS) the following year. It was a classic startup story: Sonosite hit NASDAQ immediately after launching, with no product, no approval from the Food and Drug Administration (FDA), and no revenue. 

Sonosite was acquired by Fujifilm in 2012, and Kevin left the company in 2014. 

In 2015, Kevin co-founded EchoNous, to make a handheld PoCUS device that cost significantly less than the models used as the standard in hospitals. Even more ambitious, it would use AI and ML to not only deliver more accurate results, but to improve the detail and accuracy of those results over time. The company’s AI-powered Kosmos platform was approved by the FDA in 2020. 

In this episode of Medsider, Kevin explains the pros and cons of public versus private investors, what happens when a competitor with an inferior product dominates the headlines, and why the toughest potential customers are the ones you should try to win over first.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Kevin if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Robert Kline, the Chairman of ThermoTek.

Robert left big pharma to start Medivance in 1998, which he later sold for $260 million in 2011. His next venture, ViroCyt, a spin-off from the University of Colorado, sold in 2016 for $16 million. Robert then joined startup Bolder Surgical in 2017, pivoted it, and sold the company in 2021 for $160 million. He’s now Chairman of ThermoTek.

In this episode of Medsider, Robert shares the lessons he learned from leading three medtech companies through successful acquisitions: never underestimate the importance and difficulty of fundraising, don’t assume everyone has the problem you want to solve, and don’t build your company around an exit. Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Robert if you'd rather read it instead.

In this episode of Medsider Radio, we’re sitting down with Holly Rockweiler, co-founder and CEO of Madorra.

Holly spent the early part of her career working as a research scientist for Boston Scientific. In 2013, she took a fellowship at Stanford University’s Byers Center for Biodesign, where she met her future business partner, Ryan Krone. Through the fellowship, Holly and Ryan developed Madorra, a non-hormonal medical device that treats vaginal dryness. As co-founder and CEO of Madorra, Holly’s on a mission to improve women’s health. 

In this episode of Medsider, Holly discusses the importance of listening to your patients when developing medtech solutions, and why having a cause can be a valuable motivator. She also shares her most valuable learnings from participating in Stanford's Biodesign program.  

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Holly if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Robert Fenton, the founder and CEO of Qualio, a cloud-based all-in-one quality management system (QMS) for life sciences companies. 

Prior to founding Qualio in 2012, Robert studied pharmacy for five years at the University College Cork, practiced as a community pharmacist, and spent time in quality and R&D roles at global pharmaceutical companies including Pfizer and LEO Pharma. Robert made the move to San Francisco in 2016 after bootstrapping Qualio in his home country of Ireland. 

In this episode of Medsider, Robert shares his predictions for the life sciences industry in 2022. He also discusses how Qualio can support (and not hinder) medtech and healthtech companies as they move through the complex process of taking a product from conception to the market. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Robert if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with John Murphy, President and CEO of Virtual Incision.

With a background in life sciences, aerospace, private equity, and venture capital, John co-founded Virtual Incision in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.

In this discussion,  John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with John if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Rosina Samadani, CEO of Oculogica.

Rosina Samadani initially joined Oculogica in an advisory role, supporting her neurosurgeon sister’s plan to develop EyeBOX, a diagnostic medtech device for concussions. In 2015, Rosina transitioned into her current role as President and CEO of the company. With a doctorate in biomedical engineering from MIT, Rosina has been involved with multiple startups. She also serves as a judge for Stanford’s StartX Accelerator, and MIT’s $100K Entrepreneurship Competition. 

In this discussion,  Rosina shares the importance of relationships in the regulatory and reimbursement processes, why first-time entrepreneurs shouldn’t be intimidated by complex procedures, and lessons learned from her experiences raising capital.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Rosina if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Caroline Loew, President and CEO of Glympse Bio.

Caroline has been with Glympse Bio since 2018. Prior to that, she held executive roles at Merck and Bristol Myers Squibb, where she oversaw R&D. Caroline earned her bachelor’s and doctoral degrees at Imperial College, London. 

In this discussion, Caroline shares her “early-and-often” approach to dealing with regulatory issues and outlines four things to consider ahead of conversations with potential investors. Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Caroline if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Jim Biggins, Founder and CEO of Access Vascular.

Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.

In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Jim if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with John Mastrototaro, CEO of Movano.

John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. 

In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.  Before we jump into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with John if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Justin Barad, Co-Founder and CEO of Osso VR.

Justin is an orthopedic surgeon with a passion for technology and a history of working in the video game industry. Using his experience and knowledge, he developed a virtual reality platform that can reform the way surgeons are trained and assessed.

In this conversation, Justin explains how he avoids being pulled in multiple directions with his technology, why it’s important to let potential customers get hands-on with your platform, and why tech can and should be fun — even in healthcare.

Before we jump into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Justin if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.

David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation.

In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies.  

Before we jump into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with David if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Justin Zenanko and Greg Molnar, co-founders of SynerFuse.

Justin is a Certified Public Accountant who previously led fundraising efforts at Recombinetics and Greg is the former Director of Neuromodulation Research at Medtronic. In 2018, they joined forces to build SynerFuse, a clinical-stage startup developing an innovative therapy to relieve chronic back pain.

In this discussion, the two SynerFuse co-founders share their experience launching an innovative therapy to address chronic back pain, how they are navigating challenging regulatory waters, and why they chose to invest heavily in their own venture.

Before we jump into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Justin and Greg if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Laura Yecies, CEO of Bone Health Technologies.

Laura is a Silicon Valley veteran with more than three decades of experience at major tech companies and startups. She’s always had an interest in improving people’s health and wellness and was drawn to medtech startup Bone Health Technologies, which is developing a vibration belt intended to prevent osteoporosis.

In this discussion, Laura shares why you should look for investors who are passionate about your mission, how FDA clearance can boost consumer confidence in your technology, and why patients should be at the center of everything you do.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Laura if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Olivier Delporte, CEO of Miracor Medical.

Olivier has more than 20 years of sales, marketing, and general management experience, mostly in the medical device industry. In 2016, he became the CEO of Miracor Medical, a medical device company based in Belgium. Under Olivier’s guidance, the company is advancing its flagship PiCSO treatment for severe myocardial infarction.  

In this discussion, Olivier explains why he advocates for randomized clinical trials, how remote monitoring tools can make clinical trial programs more efficient, and why startups should increase their fundraising goals.  

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Olivier if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Sina Habibi, CEO of Cognetivity.

Sina has a Ph.D. in engineering from the University of Cambridge, where he met his business partner Seyed-Mahdi Khaligh-Razavi. The two co-founded Cognetivity Neurosciences, which develops cognitive assessment tests for clinicians and patients to detect cognitive impairment, including dementia. 

In this discussion, Sina shares the importance of collaborating with regulators and end users, why he primarily focuses on the value of revenue generation versus cost savings, and the benefits of teaming up with an expert fundraiser. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Sina if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Cody Simmons, CEO of DermaSensor.

Cody spent four years learning about business strategy and analytics at biotechnology giant Genentech before becoming CEO of DermaSensor in 2016, where he leads development and commercialization efforts for the company’s novel skin cancer detection tool. In 2018, he was included on the Forbes 30 Under 30 list in healthcare.

In this discussion, Cody shares why he thinks companies need to focus on regulatory and reimbursement alignment from the very beginning, the importance of finding ally investors, and how to build trust with potential partners in your network.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Cody if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Eugene Malinskiy, CEO and Co-founder of Lazurite.

Eugene is a serial entrepreneur with expertise in the IT and medical fields. He also has hands-on experience as a medic and has worked in operating rooms throughout the country. He founded Lazurite, an innovative healthcare company focused on cutting-edge surgical and lighting technologies, in 2015. That same year, Eugene was selected as one of Forbes 30 Under 30 recipients in the manufacturing sector.

In this discussion, Eugene shares how planning out every step of ArthroFree’s regulatory strategy helped streamline the FDA clearance process, the importance of preparing for failure and being ready to solve problems, and why entrepreneurs should seek out input from investors at every step of the process. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Eugene if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Bryce Klontz, President and CEO of New View Surgical.

With over 20 years of experience working in the surgical device space from Canada to Singapore, Bryce brings a tactical advantage to his role as the CEO of New View Surgical. 

Under his leadership, New View Surgical has closed a successful Series B with a cumulative total of $14.5 million in investments and secured 510(k) clearance along the way. He previously worked as the VP of Commercial Strategy for Emerging Markets at Covidien in addition to leadership roles at several other startups.

In this discussion, Bryce shares insights from his decades of experience in the surgical devices space, from building relationships of trust with regulators and investors to working closely with practitioners to perfect product-market fit. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Bryce if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Heather Underwood, CEO of EvoEndo.

Heather is a medical device and health technology entrepreneur with a highly interdisciplinary background at the intersection of computer science, global health, human-centered design, education, and international development.

In this interview, Heather elaborates on her unique approach to innovation in the medtech arena, how fundraising isn’t one-size-fits-all, and why regulatory clearance isn’t the end of the road. Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Heather if you'd instead read it.

In this episode of Medsider Radio, we sat down with Yoav Kimchy, Founder and CTO of Check-Cap.

Yoav has more than 20 years of experience in the development and management of innovative medical device companies. In 2005, he founded Check-Cap, a clinical-stage medical diagnostics company that aims to change the colorectal cancer (CRC) screening landscape with its C-Scan ingestible capsule, tracing, and imaging system.

In this discussion, Yoav shares how early feedback from regulators can help streamline your development efforts, why you should shift your team as the company grows, and the importance of knowing when to lead and when to follow.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Yoav if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Dan Clark, President of Linear Health Sciences.

Dan Clark started his career in the private sector at Parker Hannifin, a Fortune 200 organization that he calls “the largest company you’ve never heard of.” After experiencing the medtech innovation cycle many times over, he was eager to innovate himself. In 2015, Dan teamed up with Dr. Ryan Dennis to start Linear Health Sciences, a medtech company that created the Orchid, a device designed to mitigate unwanted or accidental IV dislodgement.

In this interview, Dan explains when and how Linear raised capital, how it has navigated complex regulatory pathways, and why you need to be your own worst enemy as an innovator.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Dan if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Jennifer Ernst, CEO of Tivic Health.

Jennifer came to the medtech space after more than 20 years in the computing and electronics industries, serving in high-profile roles at Xerox PARC and Thin Film Electronics. In 2016, Jennifer founded direct-to-consumer medtech company Tivic Health and helped lead the development and commercialization of the company’s flagship device ClearUP.

In this interview, Jennifer shares how consumers can play a key role in boosting support and evidence for over-the-counter medical devices, and why she thinks direct-to-consumer business models will transform the medtech space.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Jennifer if you'd rather read it instead.

In this two-part interview, I was lucky enough to sit down with Erica Rogers, CEO of Silk Road Medical. We first spoke a few years ago and then again much more recently to catch up on what had changed at Silk Road since our first conversation.

During our catch up, we discussed how Erica led her team at Silk Road through PMA approval, successful insurance coverage and reimbursement strategy, which led to a very rewarding public offering for Silk Road, opening at $20 a share. This resulted in the opportunity to continue the company’s goal, which is to change the standard of care in carotid artery disease with their TCAR procedure.

Much of our first conversation was about Erica’s career trajectory and how she was able to successfully, and gracefully, exit multiple medtech companies. Her lengthy career and insight as a medtech thought leader is just as interesting today as it was when we recorded our conversation.

Before leading Silk Road, Erica was the COO of Medicines360, a nonprofit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical as well as the cofounder of Visiogen, which was acquired by Abbott Medical Optics in 2009.

Prior to that, Erica spent over 12 years at Boston Scientific in a variety of sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in Zoology from San Diego State University. Erica holds five issued and 15 pending US patents for medical devices in nanotechnology.

See more...

A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics. 

Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which sold to Bayer HealthCare), and Devax (which sold to Biosensors International). From 2004 through 2006, Buckman served as President of the Cardiology Division of St. Jude Medical. 

Before joining St. Jude, he served as Chairman and CEO of ev3, a company that Buckman co-founded and was later acquired by Covidien for $2.5 billion dollars in 2010.

Paul has worked in the medical device industry for over 35 years, including 10 years at Scimed Life Systems and Boston Scientific where he held several executive positions before becoming President of the Cardiology Division at Boston Scientific in January of 2000. Buckman received a BA degree in business administration and an MBA degree from Western Michigan University. 

Here are a few of the things we’re going to learn in this interview with Paul:

- Of all the medtech startups that Paul’s been a part of, the two are closest to his heart.
- Two of the many key learnings that Paul recalls during his time helping to build Scimed.
- When it comes to product development for medtech startups, why it’s critical to be ruthless about prioritization?

See more...

In late 2016, I was able to sit down with Kevin Sidow. At the time he was President & Chief Executive Officer for Moximed and had been since 2008.

Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.

Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.

Here are a few of the things we learned from Kevin:

- How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.
- What makes the Atlas System different than other orthopedic knee implants?
- How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.

See more...

After a brief hiatus from recording podcasts, it was a privilege to dust off the microphone and interview Kyle Frye. As U.S. president of SyntheticMR, Kyle is tasked with growing and expanding the brand and business in the U.S. for the Swedish-based company that is creating the future of quantitative MRI technology. Their innovative MRI software solutions support shorter exam times and deliver more information to clinicians, leading to improved diagnostic efficacies.

Prior to assuming this role in August 2019, Kyle was a Zone Vice President of Sales for Siemens and also was in leadership positions at both niche and large medtech companies including Blue Belt Technologies (now Smith & Nephew), Verathon, and Brainlab. He also worked for BioMedix for three years, working his way up from a sales rep driving 4–5 hours a day to Western Area Sales Director, which required relocation from metro Cincinnati to the San Francisco Bay area. Kyle received a B.A. degree in political science and finance from Northern Kentucky University in 2004.

Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, joined me as a special guest for this interview with Kyle. He brings a unique perspective to this discussion, having worked as a sales rep and consultant in pharma and medtech for nearly 20 years prior to transitioning to recruiting.

Here are a few of the key topics we discussed in this podcast: 

• Why a competitive spirit and winning are important, but not the “be-all and end-all” to medical device success.
• Why communicating “the why” of career moves is key to landing new opportunities.
• How being flexible and willing to relocate can help advance your career, especially in the medtech space.
• The pros and cons of working for large vs. small companies.
• Kyle’s favorite business books, the importance of having a mentor, and the advice he would tell his 25-year-old self.

Check out the rest of the show notes here...

I recently had the opportunity to interview Dan Rose, CEO of the French-based medtech company LimFlow. Founded in 2012, LimFlow transformed the peripheral vasculature space by providing a lifesaving option for end-stage critical limb-threatening ischemia (CLTI) patients facing amputation. LimFlow is designed to restore blood flow to the ischemic foot via deep vein arterialization, thereby preventing major amputation, resolving pain, and promoting wound healing. 

Prior to assuming the role of CEO at LimFlow in August 2016, Dan had more than 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, he was VP and General Manager EMEA for Direct Flow Medical, and VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company. 

Norbert Juist, an executive recruiter who specializes in medical device sales and marketing, also joined me for this interview with Dan Rose. Norbert brings a unique perspective to this discussion, having worked as a sales rep and consultant in medtech for nearly 20 years prior to transitioning to executive recruiting.

Here are a few of the topics we discuss in this episode:

• How LimFlow used a concept that’s been in existence since 1912 and transformed it into a modern therapy that multidisciplinary clinicians can reproduce.
• How Med Start played an instrumental role in the launch and ultimate success of LimFlow.
• Why it’s essential to find a physician champion willing to invest time and energy in your tech.
• Overcoming the challenges presented by an ever-evolving MDR landscape, both in the EU and US.
• Key factors you can’t ignore if you want to succeed as a first-time CEO.
• Why investing in independent market research is well worth the cost.
• Why the FDA Breakthrough Devices Program has been a game changer in the US.

See more...

Joining Medsider Radio for this episode is Beverly Huss, President and CEO of Qool Therapeutics, a development-stage company working on a novel, non-invasive therapeutic hypothermia device for the preservation of tissue following catastrophic events like a heart attack, stroke, or traumatic brain injury.

Previously, Beverly was the CEO of Vibrynt, a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. Prior to that, Beverly was the President of Guidant Endovascular Solutions (acquired by Abbott), a medical device company focused on the treatment of cardiovascular and peripheral vascular disease.

She holds an M.S. in technology management from Pepperdine University, as well as a B.S. in metallurgical engineering from the University of Illinois. Beverly also has a few patents to her credit in the cardiovascular and obesity medical device arenas.

With me on this episode is guest host, Norbert Juist, one of the most honest, genuine, and personable people I know. Norbert runs Sales Performance Resources, where he specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. 

Interview Highlights with Beverly Huss

• The origin story of Qool Therapeutics and how Beverly got involved with the company.
• The clinical trial strategy that Qool Therapeutics is following and the reasoning for it.
• Beverly’s strategic approach to making a medical device a reality, including the regulatory, clinical, and reimbursement paths that should be considered.
• Key learnings from Beverly’s time at Vibrynt. 
• The “other R&R”: the importance of resilience and relentlessness when you are raising money for a company.
• How to get the attention of medical device venture capitalists.
• Critical lessons Beverly throughout her career at ACS and Guidant.
• Beverly’s favorite books and how they inspire resiliency.
• The business leaders and mentors that Beverly most admires.
• Advice Beverly would give to her 30-year old self.

See more...

On this episode of Medsider Radio, I had the chance to sit down with Michael Tozzi, President and CEO of TAS Medical. Mike and his team are aiming to eliminate surgical mesh by converting hernia procedures to minimally invasive repairs.

Mike has over 20 years of commercial medical device experience and specializes in investor relations, sales & marketing readiness, and improving the execution of early-stage medical device companies. 

Previous to TAS Medical, Mike served as Chief Commercial Officer at Carevoyance, where he and his team created groundbreaking analytics tools designed to help medical device companies better understand their markets and execute their commercial goals.

Prior to this, Mike helped to build Cardiovascular Systems, Inc. (or CSI) from the ground floor, taking the company from an early stage to over $1.3 billion in market capitalization in just seven years. At CSI, Mike held various executive roles in sales and marketing. 

Joining me on this episode is special guest host, Norbert Juist, who runs Sales Performance Resources, which specializes in recruiting for medtech marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. 

Interview Highlights with Mike Tozzi

• The origin story of TAS Medical and how Mike got involved.
• The strategies that TAS Medical followed to go from initial product concept to eventual commercialization.
• The regulatory and clinical paths that Mike and his team considered.
• How much did the insurance coverage and reimbursement landscape factor into Mike’s early decision-making process?
• Mike’s approach to raising capital for CSI and TAS Medical. 
• Common mistakes that early-stage medtech companies make and how to avoid them.
• Mike’s favorite book, the business leader he most admires, and the advice he’d give to his 30-year-old self.

See more...

In this episode of Medsider Radio, we downloaded with Jennifer Fried, the CEO and Co-Founder of ExplORer Surgical. Jennifer founded the company with Dr. Alex Langerman as an MBA student at the University of Chicago Booth School of Business, where she received her degree with honors in finance and entrepreneurship.

Previously, Jennifer was a Vice President at Park Lane Ventures, a healthcare-focused venture capital fund spun out of Essex Woodlands. Jennifer began her career as a consultant at Bain & Company in Chicago after graduating from Northwestern University.

With me on this episode is special guest host, Norbert Juist, who runs Sales Performance Resources, where he specializes in recruiting for medical device marketing and sales positions. Prior to this, he was a sales rep at Cordis Endovascular, a spine consultant at Synthes, and a sales rep at Ethicon. 

Interview Highlights with Jennifer Fried

● How most medical device companies capture procedural data & workflow processes -- and why it’s completely outdated. 

● The challenges medtech companies are facing when it comes to educational training & product development and why they’re considering platforms like ExplORer Surgical.

● Jennifer’s favorite business book, the business leader she most admires, and the advice she’d give to herself 5-10 years ago.

See more...

I recently sat down with Katherine Ward, Chief Commercial Officer and managing director for Healthy.io. She has worked in healthcare for 28 years — including 15 years with the UK National Health Service and 11 years with United Health Group where she was the Chief Executive with United Health UK and Chief Growth Officer with Optimum International. 

In this conversation, we cover what Healthy.io does for the broader healthcare community, lessons from the COVID-19 crisis, clinical-grade population health technology, decentralized remote diagnostic screening, and how their technology works with existing health systems. 

Interview Highlights with Katherine Ward

• Who is Katherine and what is her background?
• What is Healthy.io and what challenges or problems do they solve for patients and clinicians?
• Why the time finally come for decentralized remote diagnostic screening, using urine testing as an example.
• Lessons on the importance of virtual testing from the COVID-19 crisis.
• How Healthy.io has approached the regulatory and reimbursement landscapes, including their clinical trial strategy.
• How their population health technology works together (with and within) existing healthcare systems.
• Katherine’s favorite genre of books, the leader she most admires, and the advice she’d give to her younger self.

See more...

Over the last 20 years, Dr. Tej Singh has served as the Founder and Chief of Vascular Surgery for three large, multidisciplinary vascular programs in Silicon Valley. He has vast experience with renal failure and vascular access procedures and is acutely focused on his first company, Fist Assist Devices. Dr. Singh’s company is developing the first renal care wearable device for venous enlargement and dialysis enhancement. 

In this episode, Dr. Singh and I talk about the primary challenge that First Assist Devices is trying to solve, the origin story for their first product, his approach to mapping out clinical trial strategies, and much more.      

Interview Highlights with Dr. Tej Singh

• Who is Dr. Tej Singh and what is his background?
• What are Fist Assist Devices and what challenges are they trying to solve?
• The origin story for their first product and the critical inflection points for the company.    
• How Dr. Singh evaluated the IP landscape for his first device. 
• Dr. Singh’s approach to mapping out clinical trial strategies.
• How he navigated the insurance coverage and reimbursement landscape.
• His unique approach to strategic patience and why it’s crucial for medtech startups.
• Dr. Singh’s favorite book, the leader he most admires, and the advice he’d give to his 30-year-old self.

See more...

In this episode of Medsider Radio, our guest is Matthew Amsden, the Founder, and CEO of ProofPilot, a platform designed to help people design, launch and participate in clinical trials.

ProofPilot’s mission statement revolves around making it incredibly easy to run scientifically-valid research studies. They’re dedicated to making research study participation accessible, interesting, and fun.      

In this discussion with Matthew, we chatted about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.

Interview Highlights with Matthew Amsden

• Who is Matthew Amsden and where did the idea for ProofPilot begin?    
• The importance of letting early customers try product iterations.
• How clinical studies can become a revenue driver. 
• Various types of clinical trials and how they’re conducted on the ProofPilot platform.
• Risky and costly approaches to traditional clinical studies.     
• The synergy between data, compliance, and incentives.
• How a virtual, hybrid model can solve problems when it comes to traditional clinical trials. 
• Matthew’s favorite business book, the mentor he most admires, and the advice he’d give to his 30-year-old self.

See more...

On this episode of Medsider Radio, our guest is Travis Sessions, the Founder and Chief Executive Officer of Biomerics, a leading mid-market interventional device contract manufacturer. He's also a Managing Partner of Med Venture Holdings, a unique medtech growth equity investor. With over 20 years of business management experience, Travis has successfully built and grown multiple medical device technology companies during his career. He got his start professionally at Dow Chemical and has held management positions at Microsoft and Parker Hannifin Corporation. Travis has a B.S. in Chemical Engineering from Brigham Young University and a Master’s in Business Administration from the University of Michigan.

Interview Highlights with Travis Sessions:

• Macro trends within the medtech market, including Travis’ thoughts on the future.
• Key differences between contract manufacturers (CMs) and large original equipment manufacturers (OEMs).
• Critical things that OEMs should look for when identifying and working with CMs.
• The origin story of Med Venture Holdings.
• What Travis looks for when vetting early-stage medtech ideas.
• Critical functions that need to be in place for a medical device startup to be acquired.
• Travis’ favorite book, the mentor he most admires, and the advice he’d give to his 30-year-old self.

Learn more...

This interview is a throwback to several years ago when I chatted with Dr. David Albert about his incredible journey in bringing the AliveCor ECG app to market. Here are a few things we covered:

• The amazing story of how AliveCor’s iPhone app helped save a man’s life while on an airplane!
• The roller coaster ride Dr. Albert experienced in his pursuits to develop the ECG app.
• Five key lessons you can learn from Dr. Albert’s experiences. 
• And his timeliness advice for ambitious doers, which includes the following: believe in your ideas don’t be afraid to swim against the stream.

Click here to learn more.

This interview is part of a throwback mini-series from several years ago when I chatted with my good friend, Joe Hage. He’s the CEO of Medical Marcom and Chairman of the Medical Devices Group, a community of over 350,000 medical device members. In this entertaining interview, here are some of the things we talked about:

• How Joe, with a limited medical device industry background, helped Cardiac Science become a medtech marketing leader.
• Why Joe thinks search engine optimization (SEO) is among the most important elements for your marketing mix.
• How you can use editorials to demonstrate medical device industry leadership.
• And why sending prospects to your website homepage may not be the best idea.

See more...

This interview is part of a throwback mini-series to several years ago when I chatted with Kevin Bitterman, who at the time, was with Polaris Venture Partners. He’s now a partner with Atlas Venture, but the lessons you can glean from this discussion still hold true. Namely:

• What medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success. 
• What requirements would make for an attractive IPO opportunity?
• What questions should medtech startups have already answered before approaching a potential buyer?
• And in terms of a potential exit, what is more, important for a medical device startup – clinical data or commercial traction?

See more...

This interview is a continuation of a throwback mini-series I’ve been releasing over the past few weeks with some of my favorite Medsider guests.

On this particular episode, I chatted with Randel Richner, a true expert in healthcare economics and reimbursement.  At the time of this interview, she was with Neocure Group, a company she founded and later sold to Intralign. Although this discussion is several years old and the audio quality isn’t ideal, Randel's insights are timeless. Here are some of the things we covered:

• A case study of how Randel helped save a medical device company from severe reimbursement implications.
• Randel’s unique “orchestra score” philosophy and how it aids in streamlining reimbursement strategies.
• The importance of defining the difference between how hospitals get paid and how physicians get paid.
• And what Randel means by the statement “comparative effectiveness is a code word for cost-effectiveness”.

See more...

This interview is a continuation of a throwback mini-series that I’ve been releasing over the past few weeks with some of my favorite Medsider guests of all time.

One of which is Lisa Suennen, who was then a Managing Member of Psilos Group, a healthcare-focused venture capital firm with approximately $600 million under management. Although this discussion is several years old and the audio quality isn’t the best, the insights Lisa provides are timeless. Here are some of the things we covered:

• What does Lisa think when the goal of physicians is to “dagger historical price lists."
• Why Lisa and her partners at the Psilos Group favor late-stage deals.
• Corporate venture capital arms: friend or foe? 
• And if you’re an early-stage medical device company, what is the best way to get the attention of Lisa Suennen and her peers in the VC world?

See more...

We're coming to the end of the throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.

In this discussion with Sheila Heyer, President of Heyer Regulatory Solutions and former VP of Global Regulatory Affairs at Boston Scientific, we learn where medical device companies are missing the mark when it comes to the FDA approval process. Here are some of the things we chatted about:

• The three most important steps you can take right now to get your medical device approved faster.
• Quality submissions and solid relationships: the importance of honing these two concepts in order to enhance your regulatory approval process.
• The key characteristics that great medtech regulatory professionals all have in common.

Check out the full interview here.

This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.

On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VCs in the Medtech space. Here are some of the points we covered:

• Novel ways to fund early-stage medical device companies.
• The metrics that are most important when it comes to early-stage versus late-stage medtech investing.
• Why does the FDA “runway” seem to get longer and longer over time?
• How Rich identifies and validates whether an idea is truly disruptive.

Download the transcript here.

In this episode of Medsider Radio, we caught up with Sean Saint, the CEO of Companion Medical, which recently sold to Medtronic. Sean has more than 20 years of engineering experience in medical devices and various start-ups. Here are a few topics we covered in this interview:

• How Sean and his team at Companion Medical came up with the idea for the InPen.
• Sean's advice for raising money from medtech investors.
• Companion Medical's insurance and reimbursement strategy for the InPen.

There's definitely a lot more that we cover in this discussion, but before we jump in, I wanted to mention a few things:

First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. 

So here’s what’s different: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.

I’ve never tried this before, so let me know what you think!

Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. 

Lastly, here's the link to the full interview if you'd rather read it instead.

In this episode of Medsider Radio,  we’re talking with Mike Kujak, the President & CEO of Francis Medical.

Mike breaks down Francis’ innovative new water vapor technologies, and provides some advice about developing the alpha & beta versions of a medtech product. We’ll also discuss how to navigate the early-stage regulatory environment, and hear Mike’s views on how best to plan & execute a clinical research strategy.

Then we’ll discuss fundraising strategies and ask Mike what’s next for Francis Medical as the company plans for its second-generation development program. 

But first, a bit more on Mike's background...

Most recently, Mike was the Chief Marketing Officer and Senior Vice President of International Markets for NxThera. Prior to that, he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems.

Mike received his MBA from the University of St. Thomas and has a Bachelor of Science degree in physics and chemistry from the University of South Dakota.

Before we jump into the conversation, I wanted to mention a few things:

First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. 

Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.

I’ve never tried this before, so let me know what you think!

Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. 

Lastly, here's the link to the full interview if you'd rather read it instead.

In this episode of Medsider Radio, we’re catching up with Bruce Shook, the President & CEO of Vesper Medical. Bruce is a medical device executive with more than 30 years of experience, and today, he’s sharing his insights with the Medsider community!

In this conversation, we’ll discuss key aspects of running a medtech company, from the early design and fundraising stages through an eventual sale and exit. Bruce shares his expertise on raising start-up capital, designing and prototyping products, navigating the regulatory landscape, and managing reimbursement and coverage strategies. 

But first, here’s a bit about Bruce Shook’s background:

Most recently, Bruce served as CEO of Intact Vascular, which sold to Philips. Prior to Intact Vascular and Vesper Medical, Bruce was co-founder, Director, President and CEO of Neuronetics, a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.

Previously, he was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Bruce also served as President of Abiomed, where he obtained a PMA for the first ventricular assist device. Bruce also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.

Bruce holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management. He also earned a B.S. degree in Chemical Engineering from Penn State University. 

Before we jump into the conversation, I wanted to mention a few things:

First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. 

Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.

I’ve never tried this before, so let me know what you think!

Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. 

Lastly, here's the link to the full interview if you'd rather read it instead.

We recently caught up with medtech start-up extraordinaire, Mike Wallace, who shares his insights and experiences with the Medsider community. Mike is the co-founder and CEO of DeVoro Medical, an early-stage medical device company focused on developing innovative devices for peripheral thrombectomy.

Mike says the initial idea or concept for a medtech company is just 5% of the journey. Medsider is all about shining light on that other 95%!

In this conversation with Mike, he’ll give tips to newcomers, including some mistakes entrepreneurs often make in the early stages of their companies. Mike explains how you can pivot when an idea doesn’t pan out, and he’ll give his expertise on seed-stage fundraising as well as navigating the regulatory waters. Plus, more on his current work with DeVoro, including how he started working on problems related to peripheral thrombectomy.

But first, a bit more on Mike’s medtech background:

Prior to co-founding DeVoro Medical, Mike served as Chief Technical Officer and VP of Operations for Silk Road Medical. Mike has spent most of his professional career working for medical device start-ups, some of which include Target Therapeutics (acquired by Boston Scientific), BARRX Medical (acquired by Covidien), and Baxano (acquired by Trans1). In addition, Mike has co-founded and exited three other start-ups: TW Medical and GW Medical Neuro (both acquired by Stryker Corp) and CardioProlific (acquired by Philips). 

Mike graduated with a B.S. in Mechanical Engineering from the University of Delaware, holds a M.S. in Mechanical Engineering from the University of California, Davis, and is the co-inventor or primary inventor on over 130 issued U.S. patents.

Before we jump into the conversation, I wanted to mention a few things:

First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. 

Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.

I’ve never tried this before, so let me know what you think!

Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. 

Lastly, here's the link to the full interview if you'd rather read it instead.

We recently caught up with Renee Ryan, the CEO of Cala Health, a bioelectronic medicine company that’s focused on wearable neuromodulation therapies that deliver individualized peripheral nerve stimulation. Renee has 25 years of experience in healthcare as an executive and investor, and in this episode, she shares her expertise with the Medsider community. 

Renee will discuss some common mistakes that medtech startups make, and talk about what she looks for as an investor in early-stage companies. She shares tips on navigating the regulatory waters and obtaining insurance coverage & reimbursement. Renee also gives us some key learnings from her time at Johnson & Johnson, and talks about what’s new at Cala Health, including their recent FDA breakthrough device designation. 

But first, here’s a bit more on Renee’s background:

She has 25 years of experience in the healthcare space. Previously, Renee led the medical technology investments for Johnson & Johnson Innovation on the West Coast and Asia Pacific for 8 years. While at J&J, she made over 15 new investments, including the Series A for Cala Health. Prior to her time at J&J, she was a healthcare investment banker at RW Baird, Jefferies, and Goldman Sachs. Renee has a great eye for innovation, and we’re excited to welcome her to Medsider today. 

Before we jump into the conversation, I wanted to mention a few things:

First, I’m trying something a little different with this next series of Medsider interviews, which will be focused entirely on stories from some of the most compelling medtech and healthtech startups across the globe. 

Here's the deal: I’ve asked these founders and CEOs to answer a series of questions, which I’ve converted to audio stories with the help of some professional voiceover artists. Think of these conversations almost like recorded fireside chats that you might find on Audible. They’re short and sweet, but packed with tons of great insights.

I’ve never tried this before, so let me know what you think!

Second, if you’re into learning from proven medtech and healthtech experts, and want to know when the next interview goes live, head over to Medsider.com. You can sign up for our totally free newsletter, which includes access to certain types of gated articles as well as regular content updates. 

Lastly, here's the link to the full interview if you'd rather read it instead.

In this episode of Medsider Radio, we’re talking with the CEO of Lungpacer Medical, Doug Evans. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation.

Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers & regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics and hear more about Lungpacer’s impressive technology. But first, here’s a bit more about Doug Evans and his background:

Doug started his career at GE in business development and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.

Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community. Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. 

Second, if you want even more inside info from medtech experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Doug Evans if you'd rather read it instead.